Core Viewpoint - GeneDx Holdings Corp reported better-than-expected fourth-quarter financial results, with earnings and sales surpassing analyst estimates [1] Financial Performance - Quarterly earnings were 14 cents per share, exceeding the analyst consensus estimate of 11 cents per share [1] - Quarterly sales reached $120.989 million, surpassing the analyst consensus estimate of $120.407 million [1] - The company affirmed its FY2026 sales guidance of $540 million to $555 million [1] Stock Performance - Following the earnings announcement, GeneDx shares fell by 6.1%, trading at $81.82 [1] Analyst Ratings and Price Targets - BTIG analyst Mark Massaro maintained a Buy rating on GeneDx but lowered the price target from $200 to $170 [3] - Piper Sandler analyst David Westenberg maintained an Overweight rating and reduced the price target from $160 to $130 [3]